LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA)

2 months ago 22

Talha Qureshi

Fri, January 30, 2026 astatine 8:47 AM CST 1 min read

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is 1 of the Best Small Cap Stocks Ready to Explode successful 2026. On January 26, Sam Slutsky from LifeSci Capital reiterated a Buy standing connected the banal and raised the terms people from $39 to $45. Earlier, connected January 14, Kelsey Goodwin from Piper Sandler reiterated a Buy standing connected Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) with a terms people of $40.

Analysts astatine Piper Sandler noted that the bullish standing is based connected the company’s Palazestrant. Palazestrant is simply a imaginable best-in-class for treating ER+/HER2- bosom cancer. The steadfast highlighted the drug’s implicit ER antagonism and ER degradation ability. These capabilities are expected to marque the cause an upcoming attraction successful the immense bosom crab market.

In addition, the steadfast highlighted that the institution is expecting aggregate signifier 3 trials successful 2026, which are expected to adhd further upside to the stock. Piper Sandler expects Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) to motorboat Palazestrant by adjacent year.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is focused connected the improvement of treatments for patients with bosom crab and different superior diseases. Its cardinal pipeline includes Palazestrant and OP-3136.

While we admit the imaginable of OLMA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.